Video
Expert Forum on Bladder Cancer: Nadofaragene Firadenovec for BCG-unresponsive NMIBC
Author(s):
“It is a promising drug in terms of the 3-month complete response rate,” says Chad Ritch, MD, MBA, FACS.
In this video Chad R. Ritch, MD, MBA, FACS,discusses the safety and efficacy of the novel agent nadofaragene firadenovec for patients with BCG-unresponsive non–muscle invasive bladder cancer.
This discussion is part of a larger forum on bladder cancer with Sam S. Chang, MD, MBA, and Chris B. Anderson, MD, MPH. Chang is a Patricia and Rodes Hart professor of urology and oncology at the Vanderbilt University Medical Center and chief surgical officer at the Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee. Ritch is an associate professor of urology and an associate director of UHealth International at the Miller School of Medicine, University of Miami, Florida. Anderson is an assistant professor of urology at Columbia University Irving Medical Center, Columbia University, New York City, New York.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
